ImmunoGen (IMGN) has halted a Phase II trial of its IMGN901 drug in patients with small-cell lung cancer, due to too many infections and infection-related deaths.
The Data Monitoring Committee of the study concluded that the use of IMGN901 was unlikely to demonstrate a sufficient improvement in progression-free survival. (PR)
However, ImmunoGen has initiated Phase I testing of IMGN289, a potential treatment for lung, head and neck tumors. (PR)
Shares are -9.4%.